AKT1 and diabetes mellitus: Whilst rapamycin can lead to unwanted side effects such as decreased glucose homeostasis and increased diabetes risk [58] it is likely that this is caused by activation of a feedback loop with AKT on chronic (and high dose) rapamycin inhibition of mTORC1 [59] and Ying-Yang1 interaction [58] rather than via mTORC2 inhibition.